BioTime begins Phase III clinical trials of Hextend.BERKELEY, Calif.--(BUSINESS WIRE)--Oct. 31, 1996--BioTime Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BTIM) Thursday announced that Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the of Hextend have begun at the Duke University Medical Center. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the company, the first patient undergoing surgery received Hextend as a blood plasma blood plasma n. The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended. volume expander. The surgery was completed and no adverse events were reported. BioTime, with headquarters in Berkeley, is engaged in the research and development of synthetic blood plasma volume expanders and low temperature blood substitute solutions and technology for use in surgery, emergency trauma treatment, the preservation of organs awaiting transplant and other applications. CONTACT: BioTime Inc., Berkeley Victoria Bellport, 510/845-9535 or Paul Spindler, 213/930-0811 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion